Evidence map›Paper›PMID 42812715›Full record

ReviewFrontiers in immunology2026

Anti-CD19 CAR T-cell therapy for autoimmune diseases: from exploratory clinical trials to quantitative pharmacodynamic modeling development.

Yuqin Sun, Xiao Heng, Guang Hu, Xiumei Bo

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuqin Sun *The First Clinical College, Xuzhou Medical University, Xuzhou, China.
Xiao Heng *The First Clinical College, Xuzhou Medical University, Xuzhou, China.
Guang HuNanjing IASO Biotherapeutics Co Ltd, Nanjing, China.
Xiumei BoNational Demonstration Center for Experimental Basic Medical Science Education, Xuzhou Medical University, Xuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-CD19 CAR T-cell therapy has produced major advances in treating hematologic malignancies. Recently, researchers have explored its use in autoimmune diseases. However, the complex pathogenesis and high heterogeneity of these disorders create substantial uncertainty about treatment efficacy and safety in clinical settings. Quantitative systems pharmacology (QSP) models integrate multiple pathophysiological mechanisms and map real patients onto virtual "digital twins" to simulate the

Indexed as

Antigens, CD19Autoimmune DiseasesImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesAnimalsClinical Trials as TopicHumansReceptors, Antigen, T-CellAntigens, CD19Receptors, Antigen, T-CellReceptors, Chimeric AntigenAnti-CD19 CAR Tautoimmune diseasesimmunotherapyindividualized treatmentquantitative systems pharmacology models

Identifiers

PMID42812715
PMCPMC13620333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.